patients with chronic lymphoid malignancies. The cohort consisted of patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18), multiple myeloma (MM, n=7) and non-Hodgkin's lymphoma (NHL, n=12). Twenty healthy donors were used as the control group. All samples were collected from untreated patients at the time of diagnosis. Median plasma levels of bFGF in B-CLL, NHL and MM patients were 118.8, 10.3 and 9.6 pg/ml. Median levels of VEGF in B-CLL, NHL and MM were 78.8, 41.9 and 59.7 pg/ml. Median plasma levels of bFGF and VEGF in control group were 9.3 and 57.5 pg/ml (Table 1) . Plasma levels of bFGF in chronic lymphocytic leukemia were significantly higher in comparison to control group (p<0.001, Fig. 1 ).
The differences in plasma concentrations of bFGF in multiple myeloma and non-Hodgkin's lymphoma as well as VEGF levels in all three diseases compared to control group did not reach statistical significance. Our pilot study shows that ELISA measurement of EDTA plasma levels of angiogenic factors is a feasible and reproducible method of angiogenesis assessment. Results concerning significantly increased bFGF in B-CLL are similar to work of Aguayo and coworkers (1) . It is necessary to confirm these observations by a larger study which will enable us to compare serum and plasma concentration of angiogenic factors and to correlate the data with patients' clinical outcome. Nevertheless, the preliminary results are promising and warrant further investigations.
